Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Medication Guideline Adherence Among Patients with Markedly Elevated Blood Pressure in A Real-World Setting

View ORCID ProfileYuan Lu, Chenxi Huang, Yuntian Liu, View ORCID ProfileCésar Caraballo, Shiwani Mahajan, Daisy Massey, Erica S. Spatz, Oyere Onuma, View ORCID ProfileJoseph S. Ross, View ORCID ProfileWade L. Schulz, View ORCID ProfileHarlan M. Krumholz
doi: https://doi.org/10.1101/2022.02.16.22271094
Yuan Lu
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yuan Lu
Chenxi Huang
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuntian Liu
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
César Caraballo
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for César Caraballo
Shiwani Mahajan
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daisy Massey
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erica S. Spatz
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oyere Onuma
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph S. Ross
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
3Section of General Internal Medicine, Yale School of Medicine, New Haven, CT
4Department of Health Policy and Management, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joseph S. Ross
Wade L. Schulz
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
5Center for Medical Informatics, Yale School of Medicine, New Haven, CT
6Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wade L. Schulz
Harlan M. Krumholz
1Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT
2Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
4Department of Health Policy and Management, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harlan M. Krumholz
  • For correspondence: harlan.krumholz@yale.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective To evaluate medication guideline adherence among ambulatory patients with markedly elevated blood pressure (BP), overall and by patient characteristics.

Design Population-based, retrospective cohort study.

Setting Yale New Haven Health System.

Participants Adult patients aged 18-85 years with markedly elevated BP (defined as two consecutive outpatient visits with systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg) between October 1st, 2015 and December 31st, 2018.

Main outcome measures We assessed the number and class of antihypertensive drugs (previously taken and newly prescribed) prior to 90 days of the second visit with BP ≥160/100 mmHg. Among patients treated with two-drug class regimens, we assessed the proportion of patients on guideline-recommended two drug classes, overall and stratified by documentation of prior myocardial infarction (MI), diabetes, chronic kidney disease (CKD), and uncomplicated hypertension (i.e., without MI, coronary artery disease, diabetes, CKD, and cerebrovascular disease).

Results We identified 16,377 patients with markedly elevated BP. They had a mean age of 65.8 (SD: 14.5) years; 54.0% were female; and 69.4%, 19.6%, and 9.6% were White, Black, and Hispanic, respectively. Prior to 90 days of the second visit, 29.8% had no active antihypertensive drug prescription, 20.0% had one drug class prescribed, and 50.2% had two or more drug classes prescribed. Among patients prescribed one antihypertensive drug class, the most common drug class was angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), followed by calcium channel blocker (CCB). Among patients prescribed two antihypertensive drug classes, the most common treatment combinations were ACEI or ARB and thiazide diuretic (21.0%), followed by ACEI or ARB and CCB (20.6%). Guideline-recommended two-drug class combination therapy were prescribed in 54.3% of the treated population, with the highest proportion of 67.0% in patients with a prior MI and the lowest proportion of 48.2% among patients with CKD. Older age, lower body mass index, and lower BP were associated with lower prescription of guideline-recommended combination therapy.

Conclusion Only half of patients with markedly elevated BP were prescribed guideline-recommended antihypertensive combination drugs. Major opportunities exist for improving the guideline adherence of antihypertensive drug prescription in this population.

Section 1: What is already known on this subject?Hypertension affects nearly one in two adults in the United States, of whom 20% have markedly elevated blood pressure (BP; defined as BP ≥160/100 mmHg). People with markedly elevated BP have increased risks of adverse cardiovascular and kidney events. Clinical guidelines recommend prescribing combination therapy with two or more antihypertensive agents for patients with markedly elevated BP.

Section 2: What this study adds This study quantified the real-world medication guideline adherence among ambulatory patients with markedly elevated BP, using electronic health record data from a large health system in the United States. Prior to 90 days of the second visit with BP ≥160/100 mmHg, nearly 30% of patients had no active antihypertensive drug prescription. Among patients prescribed at least one antihypertensive drug class, guideline-recommended two-drug class combination therapy were prescribed in 54% of patients, with the highest proportion of 67% in patients with a prior myocardial infarction and the lowest proportion of 48% among patients with chronic kidney disease. These findings highlight a large missed opportunity for improving the guideline adherence of antihypertensive drug prescription in this population.

Competing Interest Statement

Dr. Lu is supported by the National Heart, Lung, and Blood Institute (K12HL138037) and the Yale Center for Implementation Science. In the past three years, Dr. Krumholz received expenses and/or personal fees from UnitedHealth, Element Science, Aetna, Reality Labs, Johnson & Johnson, the Siegfried and Jensen Law Firm, Arnold and Porter Law Firm, Martin/Baughman Law Firm, and F-Prime. He is a co-founder of Refactor Health and HugoHealth, and is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid Services. Dr. Schulz collaborates with the National Center for Cardiovascular Diseases in Beijing; is a technical consultant to HugoHealth, a personal health information platform, and co-founder of Refactor Health, an AI-augmented data management platform for healthcare; is a consultant for Interpace Diagnostics Group, a molecular diagnostics company. Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938); from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International. In the past 36 months, NDS has received research support through Mayo Clinic from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938); the Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative (TCPI); the Agency for Healthcare Research and Quality (R01HS025164; R01HS025402; R03HS025517; K12HS026379); the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R56HL130496; R01HL131535; R01HL151662); the National Science Foundation; from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST)and the Patient Centered Outcomes Research Institute (PCORI) to develop a Clinical Data Research Network (LHSNet).

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study received an exemption for review from the Institutional Review Board at Yale University because EHR data are de-identified.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Technical appendix, statistical code, and dataset available from the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted February 17, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Medication Guideline Adherence Among Patients with Markedly Elevated Blood Pressure in A Real-World Setting
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Medication Guideline Adherence Among Patients with Markedly Elevated Blood Pressure in A Real-World Setting
Yuan Lu, Chenxi Huang, Yuntian Liu, César Caraballo, Shiwani Mahajan, Daisy Massey, Erica S. Spatz, Oyere Onuma, Joseph S. Ross, Wade L. Schulz, Harlan M. Krumholz
medRxiv 2022.02.16.22271094; doi: https://doi.org/10.1101/2022.02.16.22271094
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Medication Guideline Adherence Among Patients with Markedly Elevated Blood Pressure in A Real-World Setting
Yuan Lu, Chenxi Huang, Yuntian Liu, César Caraballo, Shiwani Mahajan, Daisy Massey, Erica S. Spatz, Oyere Onuma, Joseph S. Ross, Wade L. Schulz, Harlan M. Krumholz
medRxiv 2022.02.16.22271094; doi: https://doi.org/10.1101/2022.02.16.22271094

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8987)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1959)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10809)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1903)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)